Invenio Imaging has obtained the CE mark for its NIO Glioma Reveal image analysis module, which uses artificial intelligence (AI) to identify cancer during surgical procedures.
Leveraging deep learning, NIO Glioma Reveal aids neurosurgeons in detecting areas of cancer infiltration in patients who undergo initial treatment for a diffuse glioma.
With the latest development, neurosurgeons in the European Union (EU) can now use the module to guide intraoperative decisions.
Currently, the module is offered for research use only in the US and is not intended for use in diagnostic procedures.
Based in the US, Invenio Imaging is a medical device start-up that focuses on progressing the care of cancer patients by merging intraoperative fresh tissue imaging with AI.
The company’s NIO Laser Imaging System leverages Stimulated Raman Histology to image unprocessed tissue specimens without needing sectioning or staining. This facilitates histologic assessment without requiring a laboratory.
Invenio Imaging co-founder and CTO Chris Freudiger said: “By streamlining intraoperative tissue imaging, the NIO Laser Imaging System allows the imaging of multiple samples from the resection cavity.
“The NIO Glioma Reveal image analysis module now adds immediate decision support.”
As NIO images are digital, they can be shared instantaneously for analysis by pathology using the current IT infrastructure of hospitals.
Last year, the company obtained CE Mark to market the NIO Laser Imaging System in Europe for intraoperative histology.
The laser imaging system can be integrated with various other imaging techniques, including 5-ALA fluorescence to further enhance brain tumour detection during surgical procedures.